| DB ID | MyCo_5887 |
| Title | Beyond biomarkers: How enhanced CT imaging can improve the diagnostic-driven management of invasive mould disease |
| Year | 2019 |
| PMID | 31292659 |
| Fungal Diseases involved | Invasive mold infection |
| Associated Medical Condition | Hematological malignancies |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive mould infections (IMIs) are a serious complication of chemotherapy- associated immunosuppression and often compromise the intensity and timing of chemotherapy or transplantation that is essential for achieving and maintaining a complete remission in patients with hematological malignancies. As a S274 result, many hematologists administer mould-active antifungal prophylaxis during periods of prolonged neutropenia or start empirical antifungal therapy in any patient with persistent fever on broad-spectrum antibiotics, even if only a minority of patients (5–15%) will be eventually diagnosed with an IMI. |
| Technique | PCR |
| Analysis Method | qRT-PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | qRT-PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
